Sichuan Kelun-Biotech’s SKB264/MK-2870 Approved by NMPA for Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a China-based biopharmaceutical company, has received market approval...
ADC / XDC
Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline
Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...
GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review
UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...
GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study
China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...
Innovent Biologics’ IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Innovent Biologics, Inc. (HKG:...
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
VelaVigo and Avenzo Therapeutics Ink Global Partnership for Nectin4/TROP2 Bispecific ADC
Shanghai-based biotech company VelaVigo, specializing in bispecific/multi-specific antibodies and antibody drug conjugates (ADCs), has announced...
Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...
C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals
C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of...
Bliss Bio Secures NMPA Approval for BB-1712, Pioneering ADC Therapy
Bliss Bio announced that its Investigational New Drug (IND) application for the innovative antibody-drug conjugate...
GSK’s Blenrep Shows Survival Benefit in Phase III Multiple Myeloma Study
UK-based pharmaceutical company GSK plc (NYSE: GSK) has reported positive results from a Phase III...
Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...
Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu
Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
CDE Releases Technical Guidelines for Pilot Registration and Phased Manufacturing of ADCs
The Center for Drug Evaluation (CDE) has issued the “Technical Requirements for Pilot Registration and...
Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting
Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Files for New Indication with China’s NMPA
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that the National Medical Products Administration...